Ibandronate: A comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis

Journal of Bone and Mineral Research

Volumn 16, Issue 10, 2001, Pages 1871-1878

  Riis, B J ^a   Ise, J ^b,c   Von Stein, T ^b,c   Bagger, Y ^a   Christiansen, C ^a,d  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^b Roche Global Development   (Germany)

^c Roche Global Development ^*  (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Bone markers; Bone mineral density; Ibandronate; Intermittent dosing; Osteoporosis

Indexed keywords

IBANDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ADMINISTRATION, ORAL; AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; CONSUMER PRODUCT SAFETY; CROSS-OVER STUDIES; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; FEMALE; HIP; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 0034814098     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2001.16.10.1871     Document Type: Article

References (20)

1. Bisphosphonates: From the laboratory to the clinic and back again
2. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption
3. Comparison of continuous and cyclical administration of ibandronate on bone mass in ovariectomized rats
4. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: Effects on bone morphometry and mineral properties
5. Effects of ibandronate treatment on bone mass, architecture and strength in the ovariectomized cynomolgus monkey
6. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis
7. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies
8. Multicenter evaluation of Iso-ALP test kit for measurement of bone alkaline phosphatase activity in serum and plasma
9. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen
10. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine
11. Bisphosphonates: Preclinical aspects and use in osteoporosis
12. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis
13. Esophagitis associated with the use of alendronate
14. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: Prediction of bone mass changes during treatment
15. Effects of two intermittent alendronate regimens in the prevention or treatment of postmenopausal osteoporosis
16. The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study
17. Treatment with alendronate prevents fractures in women at highest risk: Results from the Fracture Intervention Trial
18. Alendronate prevents postmenopausal bone loss in women without osteoporosis
19. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
20. Mechanism of action of bisphosphonates